Tilray | TRLY - Operating Expenses

Stock Price
1.53
Daily Change
-0.11 -6.71%
Monthly
20.47%
Yearly
-34.05%
Q3 Forecast
1.63

Tilray reported $253.17M in Operating Expenses for its fiscal quarter ending in November of 2024.



Financials
Stock Price USD
Assets USD 4.19B
Cash and Equivalent USD 189.7M
Cost of Sales USD 149.73M
Current Assets USD 707.34M
Current Liabilities USD 278.52M
Debt USD 351.72M
EBIT USD -42.22M
EBITDA USD -101K
Employees USD 2.65K
EPS Earnings Per Share USD -1.78
Equity Capital and Reserves USD 3.47B
Gross Profit on Sales USD 61.22M
Interest Expense on Debt USD 7.77M
Interest Income USD 12.83M
Loan Capital USD 316.63M
Market Capitalization USD 1.18B
Net Income USD -85.34M
Operating Expenses USD 253.17M
Operating Profit USD -42.22M
Ordinary Share Capital USD 93K
Pre-Tax Profit USD -83.24M
Sales Revenues USD 308.01M
Selling and Administration Expenses USD 72.38M
Stock USD 266.01M
Trade Creditors USD 99.08M
Trade Debtors USD 112.74M

Operating Expenses Change Date
Acasti Pharma USD 3.09M 49.05M Jun/2025
Alaunos Therapeutics USD 759K 391K Dec/2024
Aurora Cannabis CAD 118.24M 66.26M Jun/2025
Avita Medical AUD 28.36M 2.44M Dec/2024
Canopy Growth CAD 94.22M 4.36M Jun/2025
Cronos Group USD 37.84M 1.5M Jun/2025
Dianthus Therapeutics USD 35.12M 1.88M Jun/2025
Divis Laboratories Ltd 17.93B 130M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
IQVIA Holdings USD 3.46B 124M Jun/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Moderna USD 1.04B 113M Jun/2025
Organigram Holdings CAD 72.9M 18.86M Jun/2025
Organon & Co USD 1.27B 144M Jun/2025
Revvity USD 629.52M 36.99M Jun/2025
Tectonic Therapeutic USD 22.33M 8.34M Jun/2025
Tilray USD 253.17M 16.55M Nov/2024
Viatris USD 3.4B 2.88B Jun/2025
Xeris Pharmaceuticals USD 67.06M 8.64M Jun/2025